Skip to Main Content

Paper Details

ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib.
Oral Oncology
1
2022
ALK, alectinib, secondary ameloblastic carcinoma
Author NameAffiliation
Zhen ZhangShanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China College of Stomatology, Shanghai Jiao Tong University, China National Clinical Research Center for Oral Diseases
Chenping ZhangShanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China College of Stomatology, Shanghai Jiao Tong University, China National Clinical Research Center for Oral Diseases
  • 1 - 2

Datasets

Release 1.2